文献速递炎症性肠病

静息期溃疡性结肠炎患者的黏膜5-氨基水杨酸浓度、药物剂型与黏膜微生物组

Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2019-03-20

研究纳入静息期溃疡性结肠炎患者,比较美沙拉秦(Mezavant)、阿沙可(Asacol)和潘他沙(Pentasa)单药治疗(4.0-4.8 g/天)下黏膜5-ASA浓度、NAT基因型与粪便/黏膜菌群的关系。美沙拉秦组黏膜5-ASA浓度最高(几何均值2.39 ng/mg),潘他沙组较低(0.57 ng/mg,降低76%,P=0.033);黏膜5-ASA浓度与黏膜细菌多样性正相关(P=0.0005)。

要点

  • 美沙拉秦组黏膜5-ASA几何均值2.39 ng/mg,高于潘他沙组0.57 ng/mg(降低76%,P=0.033)。
  • 黏膜5-ASA浓度与NAT基因型无关,但血清5-ASA浓度与NAT1基因型相关(P=0.044)。
  • 黏膜5-ASA浓度与黏膜细菌多样性正相关(P=0.0005),高浓度与变形菌门等致病菌丰度降低及粪杆菌属等有益菌丰度增加相关。

核心结论

  • 黏膜5-ASA浓度与细菌多样性及在溃疡性结肠炎中被认为有益的黏膜细菌组成正相关。
  • 美沙拉秦产生的黏膜5-ASA浓度高于潘他沙。
  • 5-ASA可能对黏膜微生物组有益,高浓度可能改善溃疡性结肠炎中的菌群失调。

研究设计与样本

  • 纳入静息期溃疡性结肠炎患者,接受美沙拉秦(n=18)、阿沙可(n=14)或潘他沙(n=10)单药治疗,剂量4.0-4.8 g/天。
  • 采用超高效液相色谱法测定结肠黏膜活检组织和血清中的5-ASA浓度。
  • 通过Sanger测序确定NAT基因型。
  • 采用Illumina Miseq平台对粪便和黏膜样本进行16S rRNA测序分析细菌微生物组。

主要发现

  • 美沙拉秦组黏膜5-ASA几何均值2.39 ng/mg,阿沙可组1.60 ng/mg(较美沙拉秦组降低33%,P=0.50),潘他沙组0.57 ng/mg(较美沙拉秦组降低76%,P=0.033)。
  • 黏膜5-ASA浓度与NAT基因型无关联,血清5-ASA浓度与NAT1基因型相关(P=0.044)。
  • 黏膜5-ASA浓度与黏膜细菌多样性正相关(P=0.0005),并与细菌组成相关。
  • 高黏膜5-ASA浓度与变形菌门(Proteobacteria)等致病菌丰度降低及粪杆菌属(Faecalibacterium)等几种有益菌丰度增加相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 5-aminosalicylic acid (5-ASA) is the first-line therapy for ulcerative colitis (UC). 5-ASA acts locally in the colonic mucosa by numerous proposed mechanisms, and is metabolised by N-acetyltransferase (NAT). Large variations in mucosal 5-ASA concentrations have been reported, but the underlying mechanisms are not understood. AIM: To study the relationship between 5-ASA concentration, 5-ASA formulation, NAT genotype and bacterial microbiome in patients with UC. METHODS: Patients with quiescent UC, using monotherapy of Mezavant (n = 18), Asacol (n = 14) or Pentasa (n = 10), 4.0-4.8 g/day were included. 5-ASA was measured in colonic mucosal biopsies and serum by ultra-high performance liquid chromatography. NAT genotypes were determined by Sanger sequencing. Bacterial microbiome was sequenced from faeces and mucosa by 16S rRNA sequencing using Illumina Miseq. RESULTS: Mezavant provided the highest mucosal 5-ASA levels (geometric mean 2.39 ng/mg), followed by Asacol (1.60 ng/mg, 33% lower, P = 0.50) and Pentasa (0.57 ng/mg, 76% lower, P = 0.033). Mucosal 5-ASA concentration was not associated with NAT genotype, but serum 5-ASA concentration and NAT1 genotype was associated (P = 0.044). Mucosal 5-ASA concentration was positively associated with mucosal bacterial diversity (P = 0.0005) and bacterial composition. High mucosal 5-ASA concentration was related to reduced abundance of pathogenic bacteria such as Proteobacteria, and increased abundance of several favourable bacteria such as Faecalibacterium. CONCLUSIONS: Mucosal 5-ASA concentration is positively associated with bacterial diversity and a mucosal bacterial composition that are perceived favourable in UC. Mezavant yielded higher mucosal 5-ASA concentrations than Pentasa. 5-ASA may have beneficial effects on the mucosal microbiome, and high concentrations possibly amend dysbiosis in UC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Olaisen M, Spigset O, Flatberg A, et al. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis. Aliment Pharmacol Ther. 2019. PMID: 30895635. doi:10.1111/apt.15227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。